STOCK TITAN

Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will participate in two upcoming healthcare conferences.

  • Tuesday, March 7th at 10:30am ET/7:30am PT, the Company will take part in a corporate panel discussion on autoimmune and inflammatory diseases and host investor meetings at the 46th Annual Cowen Healthcare Conference
  • Tuesday, March 14th at 3:20pm ET/12:20 pm PT, the Company will participate in a fireside chat and host investor meetings at the 33rd Annual Oppenheimer Healthcare Conference.

Live webcasts of the presentations will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and replays will be available on the Company's website for 90 days following the live events.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com and follow us on Twitter and LinkedIn.

Media and Investor Contact:

Temre Johnson

Alpine Immune Sciences, Inc.

ir@alpineimmunesciences.com

Source: Alpine Immune Sciences, Inc.

Alpine Immune Sciences Inc

NASDAQ:ALPN

ALPN Rankings

ALPN Latest News

ALPN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Seattle

About ALPN

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.